Quidelortho Corp (QDEL)

$21.34 -0.84 (-3.79%)
Market Cap 1.45B
Revenue (ttm) 2.78B
Net Income (ttm) -2.05B
EPS (ttm) N/A
PE Ratio 9.69
Forward PE 10.51
Profit Margin -73.74%
Debt to Equity Ratio 1.31
Volume 1,717,600
Avg Vol 1,476,814
Day's Range N/A - N/A
Shares Out 67.93M
Stochastic %K 22%
Beta 0.35
Analysts Sell
Price Target $37.67

Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, ant...

Industry: Medical Devices
Sector: Healthcare
Phone: 858 552 1100
Fax: 858 453 4338
Address:
9975 Summers Ridge Road, San Diego, United States
Chickenstick1
Chickenstick1 Nov. 14 at 3:47 PM
$QDEL I'm a buyer right here. Someone fund is having their way with it... obviously.
0 · Reply
RunnerSignals
RunnerSignals Nov. 11 at 7:18 PM
Oversold Alert $NVO $EVH $SGRY $ODD $QDEL catching eyes today Some bouncing back, others still bleeding. Who is the real bargain vs falling knife? Read the full breakdown https://stocksrunner.com/news/2025-11-11-oversold-stocks-today-show-recovery-signals
0 · Reply
Chickenstick1
Chickenstick1 Nov. 10 at 7:11 PM
$QDEL The quarter wasnt "this" bad. I still like it for a trade back to $30.
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 8:28 PM
JP Morgan has adjusted their stance on QuidelOrtho ( $QDEL ), setting the rating to Underweight with a target price of 26 → 22.
0 · Reply
Chickenstick1
Chickenstick1 Nov. 6 at 8:06 PM
$QDEL Not too disappointed with those numbers. Likely, tax loss selling today. I think this is a pretty easy trade back to $30.
1 · Reply
ZacksResearch
ZacksResearch Nov. 6 at 8:00 PM
$QDEL earnings beat expectations, but is it enough? 📉 Despite a 56.9% EPS surprise, revenues fell 3.8% on a reported basis, with Respiratory revenues dropping 32.1%. The Zacks Rank #5 (Strong Sell) reflects ongoing challenges in the broader business. Full analysis here 👉 https://www.zacks.com/stock/news/2787147/quidelortho-q3-earnings-and-revenues-beat-estimates-margins-expand?cid=sm-stocktwits-2-2787147-body-19955&ADID=SYND_STOCKTWITS_TWEET_2_2787147_BODY_19955
0 · Reply
ZacksResearch
ZacksResearch Nov. 6 at 7:00 PM
$QDEL delivers a clean Q3 beat 👏 Earnings and revenue topped estimates, fueled by strength in Labs and Immunohematology — and margins even expanded despite weaker respiratory sales. Full earnings recap here 👉 https://www.zacks.com/stock/news/2787147/quidelortho-q3-earnings-and-revenues-beat-estimates-margins-expand?cid=sm-stocktwits-2-2787147-teaser-19946&ADID=SYND_STOCKTWITS_TWEET_2_2787147_TEASER_19946
0 · Reply
mastix
mastix Nov. 6 at 6:21 PM
$QDEL This opportunities come rarely. Buy now and you will have tripled your investment in 2 years.
1 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 5:55 PM
UBS has updated their rating for QuidelOrtho ( $QDEL ) to Neutral with a price target of 31.
0 · Reply
healthcareguru
healthcareguru Nov. 6 at 5:50 PM
$QDEL this is effing stupid…buyer all day.
0 · Reply
Latest News on QDEL
QuidelOrtho Corporation (QDEL) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 5:46 AM EST - 10 days ago

QuidelOrtho Corporation (QDEL) Q3 2025 Earnings Call Transcript

QuidelOrtho Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 11 days ago

QuidelOrtho Reports Third Quarter 2025 Financial Results

QuidelOrtho Receives FDA 510(k) Clearance for VITROS™ Immunodiagnostic Products hs Troponin I Assay

Nov 3, 2025, 7:00 AM EST - 13 days ago

QuidelOrtho Receives FDA 510(k) Clearance for VITROS™ Immunodiagnostic Products hs Troponin I Assay

Informatics Illuminated: Science Bytes Podcast Explores the Power Behind Smarter Diagnostics

Oct 23, 2025, 6:45 PM EDT - 24 days ago

Informatics Illuminated: Science Bytes Podcast Explores the Power Behind Smarter Diagnostics

QuidelOrtho to Report Third Quarter 2025 Financial Results

Oct 22, 2025, 7:00 AM EDT - 25 days ago

QuidelOrtho to Report Third Quarter 2025 Financial Results

QuidelOrtho Showcases Leadership in Transfusion Medicine at AABB 2025

Oct 16, 2025, 8:30 PM EDT - 4 weeks ago

QuidelOrtho Showcases Leadership in Transfusion Medicine at AABB 2025

Through Shades of Illness: Science Bytes Podcast Discusses Why Testing Matters

Sep 25, 2025, 9:00 AM EDT - 7 weeks ago

Through Shades of Illness: Science Bytes Podcast Discusses Why Testing Matters

QuidelOrtho Announces Availability of QUICKVUE™ Influenza + SARS Test for Professional Use

Sep 22, 2025, 7:00 AM EDT - 7 weeks ago

QuidelOrtho Announces Availability of QUICKVUE™ Influenza + SARS Test for Professional Use

QuidelOrtho to Participate in the Baird 2025 Global Healthcare Conference

Aug 28, 2025, 7:30 AM EDT - 2 months ago

QuidelOrtho to Participate in the Baird 2025 Global Healthcare Conference

QuidelOrtho Completes Debt Refinancing

Aug 21, 2025, 4:30 PM EDT - 3 months ago

QuidelOrtho Completes Debt Refinancing

Science Bytes Podcast Explores How Diagnostics Can Help Protect Students and Communities

Aug 21, 2025, 9:00 AM EDT - 3 months ago

Science Bytes Podcast Explores How Diagnostics Can Help Protect Students and Communities

QuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development

Aug 19, 2025, 4:05 PM EDT - 3 months ago

QuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development

QuidelOrtho Launches Certified Analyzer Program

Aug 13, 2025, 3:00 PM EDT - 3 months ago

QuidelOrtho Launches Certified Analyzer Program

QuidelOrtho Corporation (QDEL) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 1:07 AM EDT - 3 months ago

QuidelOrtho Corporation (QDEL) Q2 2025 Earnings Call Transcript

QuidelOrtho Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 4:10 PM EDT - 3 months ago

QuidelOrtho Reports Second Quarter 2025 Financial Results

QuidelOrtho Recognized with Three Awards in 2025 IMV ServiceTrak™

Jul 29, 2025, 5:00 PM EDT - 3 months ago

QuidelOrtho Recognized with Three Awards in 2025 IMV ServiceTrak™

Urgent Need for Early Detection in Drug Overdose Cases Highlighted in New Podcast

Jul 24, 2025, 9:00 AM EDT - 4 months ago

Urgent Need for Early Detection in Drug Overdose Cases Highlighted in New Podcast

QuidelOrtho to Report Second Quarter 2025 Financial Results

Jul 22, 2025, 4:30 PM EDT - 4 months ago

QuidelOrtho to Report Second Quarter 2025 Financial Results

Real Labs, Actual Decisions With Actionable Six Sigma Metrics

Jul 17, 2025, 7:00 AM EDT - 4 months ago

Real Labs, Actual Decisions With Actionable Six Sigma Metrics

QUIDELORTHO AND BÜHLMANN LABORATORIES AG ANNOUNCE AVAILABILITY OF FECAL CALPROTECTIN (FCAL®) TURBO AND FECAL PANCREATIC ELASTASE (FPELA®) TURBO ASSAYS ON VITROS™ SYSTEMS AS A MICROTIP™ PARTNERSHIP ASSAY (MPA)

Jul 14, 2025, 7:00 AM EDT - 4 months ago

QUIDELORTHO AND BÜHLMANN LABORATORIES AG ANNOUNCE AVAILABILITY OF FECAL CALPROTECTIN (FCAL®) TURBO AND FECAL PANCREATIC ELASTASE (FPELA®) TURBO ASSAYS ON VITROS™ SYSTEMS AS A MICROTIP™ PARTNERSHIP ASSAY (MPA)

QuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs

Jul 7, 2025, 7:00 AM EDT - 4 months ago

QuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs

QuidelOrtho Announces Strategy to Accelerate Growth in Molecular Diagnostics

Jun 3, 2025, 4:10 PM EDT - 5 months ago

QuidelOrtho Announces Strategy to Accelerate Growth in Molecular Diagnostics

QuidelOrtho to Participate in Upcoming Investor Conferences

May 22, 2025, 4:30 PM EDT - 6 months ago

QuidelOrtho to Participate in Upcoming Investor Conferences

QuidelOrtho: Stagnant Growth Means Best To Avoid (Rating Downgrade)

May 12, 2025, 9:30 AM EDT - 6 months ago

QuidelOrtho: Stagnant Growth Means Best To Avoid (Rating Downgrade)

QuidelOrtho Corporation (QDEL) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:56 PM EDT - 6 months ago

QuidelOrtho Corporation (QDEL) Q1 2025 Earnings Call Transcript

QuidelOrtho Reports First Quarter 2025 Financial Results

May 7, 2025, 4:05 PM EDT - 6 months ago

QuidelOrtho Reports First Quarter 2025 Financial Results

QuidelOrtho to Report First Quarter 2025 Financial Results

Apr 23, 2025, 4:30 PM EDT - 7 months ago

QuidelOrtho to Report First Quarter 2025 Financial Results

QuidelOrtho® Introduces Results Manager™ System

Mar 10, 2025, 9:00 AM EDT - 8 months ago

QuidelOrtho® Introduces Results Manager™ System

QuidelOrtho to Participate in the 46th Annual Raymond James Institutional Investor Conference

Feb 24, 2025, 7:00 AM EST - 9 months ago

QuidelOrtho to Participate in the 46th Annual Raymond James Institutional Investor Conference

QuidelOrtho Corporation (QDEL) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 7:50 PM EST - 9 months ago

QuidelOrtho Corporation (QDEL) Q4 2024 Earnings Call Transcript

QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results

Feb 12, 2025, 4:05 PM EST - 9 months ago

QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results

QuidelOrtho Announces Preliminary Unaudited Revenue for Fourth Quarter 2024

Jan 13, 2025, 9:00 AM EST - 10 months ago

QuidelOrtho Announces Preliminary Unaudited Revenue for Fourth Quarter 2024

Kuehn Law Encourages Investors of QuidelOrtho Corporation to Contact Law Firm

Jan 7, 2025, 12:48 AM EST - 11 months ago

Kuehn Law Encourages Investors of QuidelOrtho Corporation to Contact Law Firm

QuidelOrtho to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 31, 2024, 7:00 AM EST - 11 months ago

QuidelOrtho to Present at the 43rd Annual J.P. Morgan Healthcare Conference

QuidelOrtho Announces Appointment of Two Independent Directors to its Board

Dec 10, 2024, 7:00 AM EST - 1 year ago

QuidelOrtho Announces Appointment of Two Independent Directors to its Board

Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted

Nov 20, 2024, 3:08 PM EST - 1 year ago

Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted

Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Nov 20, 2024, 8:06 AM EST - 1 year ago

Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

TGT POWL

QuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle Group

Nov 19, 2024, 9:05 PM EST - 1 year ago

QuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle Group

QuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle Group

Nov 19, 2024, 4:54 PM EST - 1 year ago

QuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle Group

Top 4 Health Care Stocks That May Plunge This Quarter

Nov 11, 2024, 6:18 AM EST - 1 year ago

Top 4 Health Care Stocks That May Plunge This Quarter

AIRS NUVB PODD

QuidelOrtho Corporation (QDEL) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 8:54 PM EST - 1 year ago

QuidelOrtho Corporation (QDEL) Q3 2024 Earnings Call Transcript

QuidelOrtho Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 4:05 PM EST - 1 year ago

QuidelOrtho Reports Third Quarter 2024 Financial Results

QuidelOrtho to Participate in Three Upcoming Investor Conferences

Oct 28, 2024, 7:00 AM EDT - 1 year ago

QuidelOrtho to Participate in Three Upcoming Investor Conferences

QuidelOrtho to Report Third Quarter 2024 Financial Results

Oct 17, 2024, 7:00 AM EDT - 1 year ago

QuidelOrtho to Report Third Quarter 2024 Financial Results

QuidelOrtho Announces New R&D Executive Leader

Oct 9, 2024, 7:00 AM EDT - 1 year ago

QuidelOrtho Announces New R&D Executive Leader

QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer

Sep 10, 2024, 7:00 AM EDT - 1 year ago

QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer

VITROS® Syphilis Assay Now Available on VITROS 3600 Immunodiagnostic System, VITROS 5600 and VITROS XT 7600 Integrated Systems in the U.S.

Aug 29, 2024, 7:00 AM EDT - 1 year ago

VITROS® Syphilis Assay Now Available on VITROS 3600 Immunodiagnostic System, VITROS 5600 and VITROS XT 7600 Integrated Systems in the U.S.

QuidelOrtho Corporation (QDEL) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 9:02 PM EDT - 1 year ago

QuidelOrtho Corporation (QDEL) Q2 2024 Earnings Call Transcript

QuidelOrtho Reports Second Quarter 2024 Financial Results

Jul 31, 2024, 4:05 PM EDT - 1 year ago

QuidelOrtho Reports Second Quarter 2024 Financial Results

Chickenstick1
Chickenstick1 Nov. 14 at 3:47 PM
$QDEL I'm a buyer right here. Someone fund is having their way with it... obviously.
0 · Reply
RunnerSignals
RunnerSignals Nov. 11 at 7:18 PM
Oversold Alert $NVO $EVH $SGRY $ODD $QDEL catching eyes today Some bouncing back, others still bleeding. Who is the real bargain vs falling knife? Read the full breakdown https://stocksrunner.com/news/2025-11-11-oversold-stocks-today-show-recovery-signals
0 · Reply
Chickenstick1
Chickenstick1 Nov. 10 at 7:11 PM
$QDEL The quarter wasnt "this" bad. I still like it for a trade back to $30.
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 8:28 PM
JP Morgan has adjusted their stance on QuidelOrtho ( $QDEL ), setting the rating to Underweight with a target price of 26 → 22.
0 · Reply
Chickenstick1
Chickenstick1 Nov. 6 at 8:06 PM
$QDEL Not too disappointed with those numbers. Likely, tax loss selling today. I think this is a pretty easy trade back to $30.
1 · Reply
ZacksResearch
ZacksResearch Nov. 6 at 8:00 PM
$QDEL earnings beat expectations, but is it enough? 📉 Despite a 56.9% EPS surprise, revenues fell 3.8% on a reported basis, with Respiratory revenues dropping 32.1%. The Zacks Rank #5 (Strong Sell) reflects ongoing challenges in the broader business. Full analysis here 👉 https://www.zacks.com/stock/news/2787147/quidelortho-q3-earnings-and-revenues-beat-estimates-margins-expand?cid=sm-stocktwits-2-2787147-body-19955&ADID=SYND_STOCKTWITS_TWEET_2_2787147_BODY_19955
0 · Reply
ZacksResearch
ZacksResearch Nov. 6 at 7:00 PM
$QDEL delivers a clean Q3 beat 👏 Earnings and revenue topped estimates, fueled by strength in Labs and Immunohematology — and margins even expanded despite weaker respiratory sales. Full earnings recap here 👉 https://www.zacks.com/stock/news/2787147/quidelortho-q3-earnings-and-revenues-beat-estimates-margins-expand?cid=sm-stocktwits-2-2787147-teaser-19946&ADID=SYND_STOCKTWITS_TWEET_2_2787147_TEASER_19946
0 · Reply
mastix
mastix Nov. 6 at 6:21 PM
$QDEL This opportunities come rarely. Buy now and you will have tripled your investment in 2 years.
1 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 5:55 PM
UBS has updated their rating for QuidelOrtho ( $QDEL ) to Neutral with a price target of 31.
0 · Reply
healthcareguru
healthcareguru Nov. 6 at 5:50 PM
$QDEL this is effing stupid…buyer all day.
0 · Reply
Staska
Staska Nov. 6 at 5:49 PM
$QDEL How is this possible after this big EPS Beat! Clearly someone is hugely invested shorting this company!!! Absolutely No Logic!!!
0 · Reply
goinbananas
goinbananas Nov. 6 at 3:40 PM
$QDEL Huge beat on EPS plus beat on rev…adding more! $ARKG $LABU
0 · Reply
Staska
Staska Nov. 6 at 5:42 AM
$QDEL QuidelOrtho’s EPS of $0.80 outperformed the forecast by 73.91%. Revenue of $700 million surpassed expectations, despite a 4% year-over-year decline. Cost savings initiatives delivered over $140 million. New product launches and innovations continue to drive growth. https://www.investing.com/news/transcripts/earnings-call-transcript-quidelorthos-q3-2025-earnings-beat-expectations-93CH-4335862
0 · Reply
Staska
Staska Nov. 4 at 4:23 PM
$QDEL https://www.prnewswire.com/news-releases/quidelortho-receives-fda-510k-clearance-for-vitros-immunodiagnostic-products-hs-troponin-i-assay-302601504.html
0 · Reply
StockBraker
StockBraker Oct. 8 at 12:47 PM
$QDEL Aligns with consensus PT of $38. Doubt we will "ever" get back to the glory days of 2021 though.
0 · Reply
JarvisFlow
JarvisFlow Oct. 7 at 11:25 AM
Citigroup has updated their rating for QuidelOrtho ( $QDEL ) to Neutral with a price target of 33.
0 · Reply
SweepCastApp
SweepCastApp Sep. 29 at 5:41 AM
$QDEL: Unusual Options Activity Alerted CALL flow observed 100x contracts at Strike price of $25 Exp on 01/16/2026 with Premium of $56K and showing BULLISH Sentiment
0 · Reply
SweepCastApp
SweepCastApp Sep. 26 at 8:59 PM
$QDEL: SWEEP CALL contracts noted 100 @ 5.60 Strike 25 Exp 01/16/2026 Premium $56.0K Sentiment BULLISH
0 · Reply
BuysSells
BuysSells Sep. 24 at 2:54 PM
$QDEL 10% drop in 2 days has forced me back in.....
0 · Reply
prismmarketview
prismmarketview Sep. 22 at 12:53 PM
$QDEL #QuidelOrtho Unveils QUICKVUE™ Influenza + SARS Test for Professional Use https://prismmarketview.com/quidelortho-unveils-quickvue-influenza-sars-test-for-professional-use/
0 · Reply
aaxaa
aaxaa Sep. 11 at 5:25 PM
$QDEL emerging from the muck
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 11 at 1:03 PM
$QDEL Great piece that accurately captures QDEL's current position. So if you want to refresh your understanding of QDEL or learn about QDEL for the first time, this is essential reading. https://beyondspx.com/quote/QDEL/analysis/quidelortho-s-strategic-reconfiguration-unlocking-value-beyond-respiratory-volatility-nasdaq-qdel
0 · Reply